Checking polyamine levels as a marker of inflammatory bowel disease

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 65 who have been diagnosed with inflammatory bowel disease (ulcerative colitis or Crohn's disease).

Age

18 to 65 years

Sex

All sexes

Disease stage

Inflammatory bowel disease (ulcerative colitis or Crohn's disease), diagnosed by the 2023 Chinese guidelines. No stage or severity is named.

Earlier treatment

People who used antibiotics or probiotics in the 8 weeks before the study start cannot join.

Main reasons for not taking part

• Other metabolic disorders
• History of cancer, severe organ problems, other severe whole-body diseases, or blood disorders
• Influenza, bacterial dysentery or another infection in the past 2 weeks
• Other diseases that may affect polyamine metabolism
• Antibiotics or probiotics in the 8 weeks before the study start

The registry criteria, word for word

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

• Are you between 18 and 65 years old?YesNo

What the trial wants to find out

Inflammatory Bowel Disease (IBD), encompassing Ulcerative Colitis (UC) and Crohn's Disease (CD), significantly impairs patients' quality of life. Current monitoring of disease activity primarily relies on endoscopy combined with histological examination, which is associated with high costs, invasiveness, poor patient tolerance, and risks of complications. Additionally, disease activity indices and laboratory-based IBD staging metrics demonstrate limited utility and accuracy in clinical practice. This study aims to investigate the correlation between polyamine levels and their key enzymes in the polyamine metabolism pathway with IBD activity, thereby establishing a predictive model for IBD progression through polyamine and metabolite measurements; to estimate the efficacy of biologics via polyamine detection, providing a scientific basis for therapeutic selection; and to screen gut microbiota associated with polyamine metabolic alterations, offering evidence-based guidance for probiotic selection in IBD patients.

The 3 groups in the trial

• IBD group

  IBD patients aged 18-65 years were categorized into remission and active-phase groups according to corresponding clinical scoring scales. IBD patients will be recruited from The First Affiliated Hospital of the Air Forth Medical University from January 2025 to December 2025.

• Healthy subjects

  Age-, gender-, and education level-matched healthy controls will be recruited from The First Affiliated Hospital of the Air Forth Medical University from January 2025 to December 2025.

• First-line biologics group

  18-65-year-old Inflammatory Bowel Disease (IBD) patients planned for the first administration of Infliximab will be recruited from The First Affiliated Hospital of the Air Forth Medical University from January 2025 to December 2025.